Massachusetts Financial Services
CRVS icon

Massachusetts Financial Services’s Corvus Pharmaceuticals CRVS Stock Holding History

Massachusetts Financial Services’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595K Sell
39,828
-1,588
-4% -$22K ﹤0.01% 939
2026
Q1 		$606K Buy
+41,416
New +$661K ﹤0.01% 883

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Massachusetts Financial Services's CRVS Position: Q2 2026 in Review

Massachusetts Financial Services reduced its Corvus Pharmaceuticals (CRVS) stake by 3.8% in Q2 2026, selling an estimated $22K and leaving 39,828 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #939.

Massachusetts Financial Services first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. The position peaked at $606K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Massachusetts Financial Services held 39,828 shares of Corvus Pharmaceuticals worth $595K as of Q2 2026.
  • Massachusetts Financial Services sold 1,588 Corvus Pharmaceuticals shares in Q2 2026, an estimated $22K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #939 holding.
  • Massachusetts Financial Services first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Massachusetts Financial Services's Corvus Pharmaceuticals position peaked at $606K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.